Leucine

Leucine

SCHEMBL1041561

CC(C)C[C@H](N)C(=O)O.O=C(N[C@@H](Cc1ccccc1)C(=O)O)c1cnccn1.OBO

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 16/20 0.63
LONP1 P36776 11/20 0.63
PSMB8 P28062 11/20 0.63
PSMB9 P28065 11/20 0.63
PSMB6 P28072 11/20 0.63
PSMB10 P40306 11/20 0.63
PSMB11 A5LHX3 10/20 0.63
PSMA7 O14818 10/20 0.63
PSMB1 P20618 10/20 0.63
PSMA1 P25786 10/20 0.63
PSMA2 P25787 10/20 0.63
PSMA3 P25788 10/20 0.63
PSMA4 P25789 10/20 0.63
PSMA5 P28066 10/20 0.63
PSMB4 P28070 10/20 0.63
PSMB3 P49720 10/20 0.63
PSMB2 P49721 10/20 0.63
PSMA6 P60900 10/20 0.63
PSMA8 Q8TAA3 10/20 0.63
PSMB7 Q99436 10/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Leucine SCHEMBL2338392 1.00 PSMB5 (0.63) PSMB5LONP1PSMB8PSMB9PSMB6
Leucine SCHEMBL2336540 1.00 PSMB5 (0.63) PSMB5LONP1PSMB8PSMB9PSMB6
Leucine SCHEMBL21955431 1.00 PSMB5 (0.63) PSMB5LONP1PSMB8PSMB9PSMB6
Leucine SCHEMBL1406108 0.97 PSMB5 (0.66) PSMB5LONP1PSMB8PSMB9PSMB6
Leucine SCHEMBL19712512 0.97 PSMB5 (0.66) PSMB5LONP1PSMB8PSMB9PSMB6
Leucine SCHEMBL28490857 0.94 PSMB5 (0.68) PSMB5LONP1PSMB8PSMB9PSMB6
Leucine SCHEMBL2931152 0.94 PSMB5 (0.68) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL20496418 0.90 PSMB5 (0.58) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL2344285 0.88 PSMB5 (0.60) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL2126381 0.87 PSMB5 (0.72) PSMB5LONP1PSMB8PSMB9PSMB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000529-B2 Synthesis of boronic ester and acid compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2018-06-19 US claimed
US-20180044377-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. 2018-02-15 US claimed
EP-2443128-B1 New synthetic route for the preparation of alpha-amino boronic esters LEK PHARMACEUTICALS (SI) 2017-12-20 EP claimed
US-20120231993-A1 NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ALPHA-AMINO BORONIC ACID DERIVATIVES via SUBSTITUTED ALK-1-YNES LEK PHARMACEUTICALS D.D. (SI) 2012-09-13 US claimed
EP-2377868-A1 Synthesis of Bortezomib MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-10-19 EP claimed
EP-4008721-B1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARM INC (US) 2024-01-03 EP disclosed
US-11376268-B2 Methods and materials for treating human immunodeficiency virus infections MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2022-07-05 US disclosed
US-20220204558-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARM INC (US) 2022-06-30 US disclosed
EP-4008721-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS Millennium Pharmaceuticals, Inc. (US) 2022-06-08 EP disclosed
US-20210395301-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARM INC (US) 2021-12-23 US disclosed
EP-3385267-B1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARM INC (US) 2021-09-29 EP disclosed
CN-108329337-B Synthesis of boronic ester and acid compounds 千禧药品公司 2021-06-25 CN disclosed
WO-2010146172-A2 NEW SYNTHETIC ROUTE FOR THE PREPARATION OF α-AMINO BORONIC ACID DERIVATIVES VIA SUBSTITUTED ALK-1-YNES LEK PHARMACEUTICALS D.D. (SI) 2010-12-23 WO disclosed
WO-2010146172-A2 NEW SYNTHETIC ROUTE FOR THE PREPARATION OF α-AMINO BORONIC ACID DERIVATIVES VIA SUBSTITUTED ALK-1-YNES LEK PHARMACEUTICALS D.D. (SI) 2010-12-23 WO disclosed
US-20100174072-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-07-08 US disclosed
US-7714159-B2 contacting the boronate complex of formula with Lewis acid catalyst in presence of a coordinating ether solvent having low miscibililty in water MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-05-11 US disclosed
WO-2009004350-A1 METHODS FOR PREPARING BORTEZOMIB AND INTERMEDIATES USED IN ITS MANUFACTURE PLIVA HRVATSKA D.O.O. (HR) 2009-01-08 WO disclosed
EP-1756121-A2 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-02-28 EP disclosed
US-20050240047-A1 contacting the boronate complex of formula with Lewis acid catalyst in presence of a coordinating ether solvent having low miscibililty in water MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-27 US disclosed
WO-2005097809-A2 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000529-B2 Synthesis of boronic ester and acid compounds BTD, BCL6, BRAP PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885
US-20220204558-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS BTD, BCL6, BRAP PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885
US-20180044377-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS BTD, BCL6, BRAP PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885
US-20210395301-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS BTD, BCL6, BRAP PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885
US-20100174072-A1 SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS BTD, BCL6, BRAP PSMB5 17/4885LONP1 2151/4885PSMB8 43/4885
US-20050240047-A1 contacting the boronate complex of formula with Lewis acid catalyst in presence of a coordinating ether solvent having low miscibililty in water PSMC2, PSMC1, PSMC5 PSMB5 35/4885LONP1 1346/4885PSMB8 29/4885
US-20120231993-A1 NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ALPHA-AMINO BORONIC ACID DERIVATIVES via SUBSTITUTED ALK-1-YNES ALK, ABL2, ALKBH3 PSMB5 2449/4885LONP1 4057/4885PSMB8 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.